Status:
ACTIVE_NOT_RECRUITING
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
Lead Sponsor:
Thomas Jefferson University
Conditions:
Glioblastoma
Malignant Solid Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. Studying samples of blood and tissue from patients with glioblastoma...
Detailed Description
PRIMARY OBJECTIVES: I. Assessment of cell yield and percentage of viable cells upon tissue receipt at the cell processing facility. II. Obtain discarded tumor tissue from surgical resections for fur...
Eligibility Criteria
Inclusion
- Provide signed and dated informed consent form
- Any individual \>= 18 years old
- Patients must have GBM or other solid tumor and undergoing surgery for diagnostic and therapeutic purposes
Exclusion
- Individuals less than 18 years old
- Unable to understand and give consent
- Patients who are not surgical candidates
Key Trial Info
Start Date :
February 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT04822688
Start Date
February 3 2021
End Date
December 31 2025
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107